Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor.

Farutin V, Prod'homme T, McConnell K, Washburn N, Halvey P, Etzel CJ, Guess J, Duffner J, Getchell K, Meccariello R, Gutierrez B, Honan C, Zhao G, Cilfone NA, Gunay NS, Hillson JL, DeLuca DS, Saunders KC, Pappas DA, Greenberg JD, Kremer JM, Manning AM, Ling LE, Capila I.

Arthritis Res Ther. 2019 Oct 23;21(1):216. doi: 10.1186/s13075-019-1999-3.

2.

Circulating Markers of Inflammation Persist in Children and Adults With Giant Aneurysms After Kawasaki Disease.

Lech M, Guess J, Duffner J, Oyamada J, Shimizu C, Hoshino S, Farutin V, Bulik DA, Gutierrez B, Sarvaiya H, Kapoor B, Koppes L, Saldova R, Stockmann H, Albrecht S, McManus C, Rudd PM, Kaundinya GV, Manning AM, Bosques CJ, Kahn AM, Daniels LB, Gordon JB, Tremoulet AH, Capila I, Gunay NS, Ling LE, Burns JC.

Circ Genom Precis Med. 2019 Apr;12(4):e002433. doi: 10.1161/CIRCGEN.118.002433. Epub 2019 Mar 7.

PMID:
30844302
3.

Characterization of Endogenous Human FcγRIII by Mass Spectrometry Reveals Site, Allele and Sequence Specific Glycosylation.

Washburn N, Meccariello R, Duffner J, Getchell K, Holte K, Prod'homme T, Srinivasan K, Prenovitz R, Lansing J, Capila I, Kaundinya G, Manning AM, Bosques CJ.

Mol Cell Proteomics. 2019 Mar;18(3):534-545. doi: 10.1074/mcp.RA118.001142. Epub 2018 Dec 17.

4.

M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study.

Ling LE, Hillson JL, Tiessen RG, Bosje T, van Iersel MP, Nix DJ, Markowitz L, Cilfone NA, Duffner J, Streisand JB, Manning AM, Arroyo S.

Clin Pharmacol Ther. 2019 Apr;105(4):1031-1039. doi: 10.1002/cpt.1276. Epub 2018 Dec 4.

5.

Can Predictive Modeling Identify Head and Neck Oncology Patients at Risk for Readmission?

Manning AM, Casper KA, Peter KS, Wilson KM, Mark JR, Collar RM.

Otolaryngol Head Neck Surg. 2018 Oct;159(4):669-674. doi: 10.1177/0194599818775938. Epub 2018 May 22.

PMID:
29783911
6.

Characterizing Decisional Conflict for Caregivers of Children With Obstructive Sleep Apnea Without Tonsillar Hypertrophy.

Manning AM, Duggins AL, Tiemeyer KA, Mullen LA, Crisalli JA, Cohen AP, Ishman SL.

J Clin Sleep Med. 2018 May 15;14(5):849-855. doi: 10.5664/jcsm.7122.

7.

Thyroid Ultrasound-Guided Fine-Needle Aspiration Cytology Results: Observed Increase in Indeterminate Rate over the Past Decade.

Manning AM, Yang H, Falciglia M, Mark JR, Steward DL.

Otolaryngol Head Neck Surg. 2017 Apr;156(4):611-615. doi: 10.1177/0194599816688190. Epub 2017 Jan 24.

PMID:
28118554
8.

Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors.

Ortiz DF, Lansing JC, Rutitzky L, Kurtagic E, Prod'homme T, Choudhury A, Washburn N, Bhatnagar N, Beneduce C, Holte K, Prenovitz R, Child M, Killough J, Tyler S, Brown J, Nguyen S, Schwab I, Hains M, Meccariello R, Markowitz L, Wang J, Zouaoui R, Simpson A, Schultes B, Capila I, Ling L, Nimmerjahn F, Manning AM, Bosques CJ.

Sci Transl Med. 2016 Nov 16;8(365):365ra158.

PMID:
27856797
9.

Fc-gamma receptors: Attractive targets for autoimmune drug discovery searching for intelligent therapeutic designs.

Bosques CJ, Manning AM.

Autoimmun Rev. 2016 Nov;15(11):1081-1088. doi: 10.1016/j.autrev.2016.07.035. Epub 2016 Aug 1. Review.

PMID:
27491569
10.

A Quantitative Microtiter Assay for Sialylated Glycoform Analyses Using Lectin Complexes.

Srinivasan K, Roy S, Washburn N, Sipsey SF, Meccariello R, Meador JW 3rd, Ling LE, Manning AM, Kaundinya GV.

J Biomol Screen. 2015 Jul;20(6):768-78. doi: 10.1177/1087057115577597. Epub 2015 Apr 7.

11.

Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity.

Washburn N, Schwab I, Ortiz D, Bhatnagar N, Lansing JC, Medeiros A, Tyler S, Mekala D, Cochran E, Sarvaiya H, Garofalo K, Meccariello R, Meador JW 3rd, Rutitzky L, Schultes BC, Ling L, Avery W, Nimmerjahn F, Manning AM, Kaundinya GV, Bosques CJ.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1297-306. doi: 10.1073/pnas.1422481112. Epub 2015 Mar 2. Erratum in: Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):E4339.

12.

Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.

Chang YS, Graves B, Guerlavais V, Tovar C, Packman K, To KH, Olson KA, Kesavan K, Gangurde P, Mukherjee A, Baker T, Darlak K, Elkin C, Filipovic Z, Qureshi FZ, Cai H, Berry P, Feyfant E, Shi XE, Horstick J, Annis DA, Manning AM, Fotouhi N, Nash H, Vassilev LT, Sawyer TK.

Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):E3445-54. doi: 10.1073/pnas.1303002110. Epub 2013 Aug 14.

13.

The kinase activities of interleukin-1 receptor associated kinase (IRAK)-1 and 4 are redundant in the control of inflammatory cytokine expression in human cells.

Song KW, Talamas FX, Suttmann RT, Olson PS, Barnett JW, Lee SW, Thompson KD, Jin S, Hekmat-Nejad M, Cai TZ, Manning AM, Hill RJ, Wong BR.

Mol Immunol. 2009 Apr;46(7):1458-66. doi: 10.1016/j.molimm.2008.12.012. Epub 2009 Jan 31.

PMID:
19181383
14.

Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.

Hill RJ, Dabbagh K, Phippard D, Li C, Suttmann RT, Welch M, Papp E, Song KW, Chang KC, Leaffer D, Kim YN, Roberts RT, Zabka TS, Aud D, Dal Porto J, Manning AM, Peng SL, Goldstein DM, Wong BR.

J Pharmacol Exp Ther. 2008 Dec;327(3):610-9. doi: 10.1124/jpet.108.139006. Epub 2008 Sep 5.

PMID:
18776065
15.

Impact of the human genome on the discovery of immune-modulatory therapeutics.

Manning AM.

Curr Opin Investig Drugs. 2006 May;7(5):406-11. No abstract available.

PMID:
16729715
16.

Assessment of the prevalence of heart murmurs in overtly healthy cats.

Côté E, Manning AM, Emerson D, Laste NJ, Malakoff RL, Harpster NK.

J Am Vet Med Assoc. 2004 Aug 1;225(3):384-8.

PMID:
15328713
17.

Targeting JNK for therapeutic benefit: from junk to gold?

Manning AM, Davis RJ.

Nat Rev Drug Discov. 2003 Jul;2(7):554-65. Review.

PMID:
12815381
18.

Screening for inhibitors of transcription factors using luciferase reporter gene expression in transfected cells.

Phippard D, Manning AM.

Methods Mol Biol. 2003;225:19-23. Review. No abstract available.

PMID:
12769470
19.

Oxygen therapy and toxicity.

Manning AM.

Vet Clin North Am Small Anim Pract. 2002 Sep;32(5):1005-20, v. Review.

PMID:
12380161
20.

Differential requirement for NF-kappaB-inducing kinase in the induction of NF-kappaB by IL-1beta, TNF-alpha, and Fas.

Russo MP, Bennett BL, Manning AM, Brenner DA, Jobin C.

Am J Physiol Cell Physiol. 2002 Jul;283(1):C347-57.

21.

Electrolyte disorders.

Manning AM.

Vet Clin North Am Small Anim Pract. 2001 Nov;31(6):1289-321, vii-viii. Review.

PMID:
11727338
22.

SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase.

Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, Anderson DW.

Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13681-6.

23.

TAK1/JNK and p38 have opposite effects on rat hepatic stellate cells.

Schnabl B, Bradham CA, Bennett BL, Manning AM, Stefanovic B, Brenner DA.

Hepatology. 2001 Nov;34(5):953-63.

PMID:
11679966
24.

Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation.

Tak PP, Gerlag DM, Aupperle KR, van de Geest DA, Overbeek M, Bennett BL, Boyle DL, Manning AM, Firestein GS.

Arthritis Rheum. 2001 Aug;44(8):1897-907.

25.

c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis.

Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, Manning AM, Firestein GS.

J Clin Invest. 2001 Jul;108(1):73-81. Erratum in: J Clin Invest 2001 Dec;108(12):1883.

26.
27.

NF-kappaB stimulates inducible nitric oxide synthase to protect mouse hepatocytes from TNF-alpha- and Fas-mediated apoptosis.

Hatano E, Bennett BL, Manning AM, Qian T, Lemasters JJ, Brenner DA.

Gastroenterology. 2001 Apr;120(5):1251-62.

PMID:
11266388
28.

Differential role of I kappa B kinase 1 and 2 in primary rat hepatocytes.

Schwabe RF, Bennett BL, Manning AM, Brenner DA.

Hepatology. 2001 Jan;33(1):81-90.

PMID:
11124824
29.

Inhibitors of NF-kappaB and AP-1 gene expression: SAR studies on the pyrimidine portion of 2-chloro-4-trifluoromethylpyrimidine-5-[N-(3', 5'-bis(trifluoromethyl)phenyl)carboxamide].

Palanki MS, Erdman PE, Gayo-Fung LM, Shevlin GI, Sullivan RW, Goldman ME, Ransone LJ, Bennett BL, Manning AM, Suto MJ.

J Med Chem. 2000 Oct 19;43(21):3995-4004.

PMID:
11052805
30.
31.

Detection and purification of a multiprotein kinase complex from mammalian cells. IKK signalsome.

Mercurio F, Young DB, Manning AM.

Methods Mol Biol. 2000;99:109-25. Review. No abstract available.

PMID:
10909081
32.

The effect of a T cell-specific NF-kappa B inhibitor on in vitro cytokine production and collagen-induced arthritis.

Gerlag DM, Ransone L, Tak PP, Han Z, Palanki M, Barbosa MS, Boyle D, Manning AM, Firestein GS.

J Immunol. 2000 Aug 1;165(3):1652-8.

33.

Management of the uncomplicated canine diabetic.

Labato MA, Manning AM.

Semin Vet Med Surg (Small Anim). 1997 Nov;12(4):248-58. Review.

PMID:
10889873
34.

Primary human CD4+ T cells contain heterogeneous I kappa B kinase complexes: role in activation of the IL-2 promoter.

Khoshnan A, Kempiak SJ, Bennett BL, Bae D, Xu W, Manning AM, June CH, Nel AE.

J Immunol. 1999 Nov 15;163(10):5444-52.

35.

NF-kappaB as a primary regulator of the stress response.

Mercurio F, Manning AM.

Oncogene. 1999 Nov 1;18(45):6163-71. Review.

36.

Jun N-terminal kinase in rheumatoid arthritis.

Han Z, Boyle DL, Aupperle KR, Bennett B, Manning AM, Firestein GS.

J Pharmacol Exp Ther. 1999 Oct;291(1):124-30.

PMID:
10490895
37.

Gene-regulating protein kinases as important anti-inflammatory targets.

Bhagwat SS, Manning AM, Hoekstra MF, Lewis A.

Drug Discov Today. 1999 Oct;4(10):472-479.

PMID:
10481143
38.

New targets for anti-inflammatory drugs.

Lewis AJ, Manning AM.

Curr Opin Chem Biol. 1999 Aug;3(4):489-94. Review.

PMID:
10419850
39.

NF-kappa B regulation by I kappa B kinase in primary fibroblast-like synoviocytes.

Aupperle KR, Bennett BL, Boyle DL, Tak PP, Manning AM, Firestein GS.

J Immunol. 1999 Jul 1;163(1):427-33.

40.

Signal transduction and transcription factors in rheumatic disease.

Firestein GS, Manning AM.

Arthritis Rheum. 1999 Apr;42(4):609-21. Review. No abstract available.

41.

Multiple signals converging on NF-kappaB.

Mercurio F, Manning AM.

Curr Opin Cell Biol. 1999 Apr;11(2):226-32. Review.

PMID:
10209157
42.

AP-1 and NF-kappaB regulation in rheumatoid arthritis and murine collagen-induced arthritis.

Han Z, Boyle DL, Manning AM, Firestein GS.

Autoimmunity. 1998;28(4):197-208.

PMID:
9892501
43.

IkappaB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex.

Mercurio F, Murray BW, Shevchenko A, Bennett BL, Young DB, Li JW, Pascual G, Motiwala A, Zhu H, Mann M, Manning AM.

Mol Cell Biol. 1999 Feb;19(2):1526-38.

44.

Identification of the receptor component of the IkappaBalpha-ubiquitin ligase.

Yaron A, Hatzubai A, Davis M, Lavon I, Amit S, Manning AM, Andersen JS, Mann M, Mercurio F, Ben-Neriah Y.

Nature. 1998 Dec 10;396(6711):590-4.

PMID:
9859996
45.

Role of IKK1 and IKK2 in lipopolysaccharide signaling in human monocytic cells.

O'Connell MA, Bennett BL, Mercurio F, Manning AM, Mackman N.

J Biol Chem. 1998 Nov 13;273(46):30410-4.

46.

Targeting the NFkappaB activation pathway for gene regulating drugs.

Manning AM.

Curr Opin Drug Discov Devel. 1998 Sep;1(2):147-56. No abstract available.

PMID:
19649814
47.

Selective inhibition of TNF-alpha induced cell adhesion molecule gene expression by tanapox virus.

Paulose M, Bennett BL, Manning AM, Essani K.

Microb Pathog. 1998 Jul;25(1):33-41.

PMID:
9705247
48.

Inhibition of NF-kappa-B cellular function via specific targeting of the I-kappa-B-ubiquitin ligase.

Yaron A, Gonen H, Alkalay I, Hatzubai A, Jung S, Beyth S, Mercurio F, Manning AM, Ciechanover A, Ben-Neriah Y.

EMBO J. 1997 Nov 3;16(21):6486-94.

49.

Generation and characterization of a novel adhesion function blocking monoclonal antibody recognizing both rat and mouse E-selectin.

Walter UM, Ayer LM, Manning AM, Frenette PS, Wagner DD, Hynes RO, Wolitzky BA, Issekutz AC.

Hybridoma. 1997 Aug;16(4):355-61.

PMID:
9309426
50.

Characterization of a novel adhesion function blocking monoclonal antibody to rat/mouse P-selectin generated in the P-selectin-deficient mouse.

Walter UM, Ayer LM, Wolitzky BA, Wagner DD, Hynes RO, Manning AM, Issekutz AC.

Hybridoma. 1997 Jun;16(3):249-57.

PMID:
9219035

Supplemental Content

Loading ...
Support Center